Molekulargenetische Diagnostik
Praxis Dr. Mato Nagel

Erbliche Lebererkrankungen

Die Gruppe der erblichen Lebererkarankungen fasst Erbkrankheiten mit ganz unterschiedlicher Pathogenese zusammen. Meist sind es Stoffwechselstörungen oder Fehlbildungen, die zu einer chronischen Leberschädigung führen.

Gliederung

Genetisch bedingte Erkrankungen
Erbliche Augenerkrankungen und Sehstörungen
Erbliche Blutkrankheiten und Gerinnungsstörungen
Erbliche Bronchial- und Lungenerkrankungen
Erbliche Erkrankungen im Hals-Nasen-Ohren-Bereich
Erbliche Fehlbildungen
Erbliche Gefäßerkrankungen
Erbliche Herzerkrankungen
Erbliche Infektionsanfälligkeiten
Erbliche Knochenerkrankungen
Erbliche Lebererkrankungen
Acoeruloplasminämie/Hypocoeruloplasminämie
CP
Caroli Erkrankung
PKHD1
Genetisch bedingte Hyperbilirubinämie
Crigler-Najjar-Syndrom 1
UGT1A
Crigler-Najjar-Syndrom 2
UGT1A
Familiäre transiente neonatale Hyperbilirubinämie
UGT1A
Gilbert-Syndrom
UGT1A
Hyperbilirubinämie vom Rotor-Typ
SLCO1B1
SLCO1B3
Hämochromatose
Hämochromatose 1
BMP2
HFE
Hämochromatose 2a
HFE2
Hämochromatose 2b
HAMP
Hämochromatose 3
TFR2
Hämochromatose 4
SLC40A1
Hämochromatose 5
FTH1
Morbus Fabry
GLA
Polyzystische Lebererkrankung
LRP5
Polyzystische Lebererkrankung 1
PRKCSH
Polyzystische Lebererkrankung 2
SEC63
Erbliche Nervenerkrankungen
Erbliche Nierenerkrankungen
Erbliche Pankreaserkrankungen
Erbliche Stoffwechselerkrankungen
Erbliche Tumorerkrankungen
Erbliche endokrinologische Erkrankungen
Erbliche immunologische Erkrankungen
Erblicher Bluthochdruck

Referenzen:

1.

de Sousa M et. al. (1994) Iron overload in beta 2-microglobulin-deficient mice.

[^]
2.

Milet J et. al. (2007) Common variants in the BMP2, BMP4, and HJV genes of the hepcidin regulation pathway modulate HFE hemochromatosis penetrance.

[^]
3.

Hentze MW et. al. (1986) Cloning, characterization, expression, and chromosomal localization of a human ferritin heavy-chain gene.

[^]
4.

Cragg SJ et. al. (1985) Genes for the 'H' subunit of human ferritin are present on a number of human chromosomes.

[^]
5.

Simon M et. al. (1977) Heredity of idiopathic haemochromatosis.

[^]
6.

Halliday JW et. al. (1977) Serum-ferritin in diagnosis of haemochromatosis. A study of 43 families.

[^]
7.

Cox TM et. al. (1978) Uptake of iron by duodenal biopsy specimens from patients with iron-deficiency anaemia and primary haemochromatosis.

[^]
8.

Sargent T et. al. (1979) Reduced chromium retention in patients with hemochromatosis, a possible basis of hemochromatotic diabetes.

[^]
9.

Feller ER et. al. (1977) Familial hemochromatosis. Physiologic studies in the precirrhotic stage of the disease.

[^]
10.

Beaumont C et. al. (1979) Serum ferritin as a possible marker of the hemochromatosis allele.

[^]
11.

Cartwright GE et. al. (1979) Hereditary hemochromatosis. Phenotypic expression of the disease.

[^]
12.

None (1979) Genetic linkage and hemosiderosis.

[^]
13.

Kravitz K et. al. (1979) Genetic linkage between hereditary hemochromatosis and HLA.

[^]
14.

Walsh CH et. al. (1978) Proliferative retinopathy in a patient with diabetes mellitus and idiopathic haemochromatosis.

[^]
15.

Lipinski M et. al. (1978) Idiopathic hemochromatosis: linkage with HLA.

[^]
16.

Kühnl P et. al. (1978) HLA antigens in patients with idiopathic hemochromatosis (IH).

[^]
17.

Cartwright GE et. al. (1978) Inheritance of hemochromatosis: linkage to HLA.

[^]
18.

Lamon JM et. al. (1979) Idiopathic hemochromatosis in a young female. A case study and review of the syndrome in young people.

[^]
19.

None (1979) Clinical conferences at The Johns Hopkins Hospital. Familial hemochromatosis.

[^]
20.

Simon M et. al. (1977) Heredity of idiopathic haemochromatosis: a study of 106 families.

[^]
21.

Edwards CQ et. al. (1977) Hereditary hemochromatosis. Diagnosis in siblings and children.

[^]
22.

Rowe JW et. al. (1977) Familial hemochromatosis: characteristics of the precirrhotic stage in a large kindred.

[^]
23.

Simon M et. al. (1977) Idiopathic hemochromatosis. Demonstration of recessive transmission and early detection by family HLA typing.

[^]
24.

Wands JR et. al. (1976) Normal serum ferritin concentrations in precirrhotic hemochromatosis.

[^]
25.

Simon M et. al. (1976) Association of HLA-A3 and HLA-B14 antigens with idiopathic haemochromatosis.

[^]
26.

Boretto J et. al. (1992) Anonymous markers located on chromosome 6 in the HLA-A class I region: allelic distribution in genetic haemochromatosis.

[^]
27.

Yaouanq J et. al. (1992) Familial screening for genetic haemochromatosis by means of DNA markers.

[^]
28.

Kaikov Y et. al. (1992) Primary hemochromatosis in children: report of three newly diagnosed cases and review of the pediatric literature.

[^]
29.

Rabinovitz M et. al. (1992) Association between heterozygous alpha 1-antitrypsin deficiency and genetic hemochromatosis.

[^]
30.

Milman N et. al. (1992) An HLA study in 74 Danish haemochromatosis patients and in 21 of their families.

[^]
31.

Zappone E et. al. (1991) Polymorphism in a ferritin H gene from chromosome 6p.

[^]
32.

None (1992) Intrafamilial variation in hereditary hemochromatosis.

[^]
33.

Milman N et. al. (1992) Transferrin subtypes in 51 Danish patients with hereditary haemochromatosis and in 847 normal subjects.

[^]
34.

Summers KM et. al. (1991) Fine mapping of a human chromosome 6 ferritin heavy chain pseudogene: relevance to haemochromatosis.

[^]
35.

Dokal I et. al. (1991) Detection of hereditary haemochromatosis in an HLA-identical pedigree showing discordance between HLA class I genes and the disease locus.

[^]
36.

Bullen JJ et. al. (1991) Hemochromatosis, iron and septicemia caused by Vibrio vulnificus.

[^]
37.

None (1991) Hereditary haemochromatosis in Denmark 1950-1985. Clinical, biochemical and histological features in 179 patients and 13 preclinical cases.

[^]
38.

Jouanolle AM et. al. (1990) HLA class I gene polymorphism in genetic hemochromatosis.

[^]
39.

Lord DK et. al. (1990) Molecular analysis of the human MHC class I region in hereditary haemochromatosis. A study by pulsed-field gel electrophoresis.

[^]
40.

Dugast IJ et. al. (1990) Identification of two human ferritin H genes on the short arm of chromosome 6.

[^]
41.

Leggett BA et. al. (1990) Prevalence of haemochromatosis amongst asymptomatic Australians.

[^]
42.

Borecki IB et. al. (1990) Percent transferrin saturation in segregating hemochromatosis.

[^]
43.

Milman N et. al. (1990) Family studies of hereditary hemochromatosis in Denmark and the Faroe Islands.

[^]
44.

Borecki IB et. al. (1990) Combined segregation and linkage analysis of genetic hemochromatosis using affection status, serum iron, and HLA.

[^]
45.

David V et. al. (1989) Ferritin H gene polymorphism in idiopathic hemochromatosis.

[^]
46.

Summers KM et. al. (1989) HLA determinants in an Australian population of hemochromatosis patients and their families.

[^]
47.

Borecki IB et. al. (1989) Segregation of genetic hemochromatosis indexed by latent capacity of transferrin.

[^]
48.

Cragg SJ et. al. (1988) HLA class I and H ferritin gene polymorphisms in normal subjects and patients with haemochromatosis.

[^]
49.

David V et. al. (1986) DNA polymorphism related to the idiopathic hemochromatosis gene: evidence in a recombinant family.

[^]
50.

Meyer TE et. al. (1987) The HLA linked iron loading gene in an Afrikaner population.

[^]
51.

Lucotte G et. al. (1986) Association between a 10 kb Pvu II restriction fragment of genomic DNA with the hemochromatosis gene.

[^]
52.

Diamond T et. al. (1989) Osteoporosis in hemochromatosis: iron excess, gonadal deficiency, or other factors?

[^]
53.

McGill JR et. al. (1987) Human ferritin H and L sequences lie on ten different chromosomes.

[^]
54.

None (1988) Immune tolerance in nonhemophilic patients with antibodies to factor VIII.

[^]
55.

Karlsson M et. al. (1988) Prevalence of hemochromatosis in Finland.

[^]
56.

Milman N et. al. (1988) HLA determinants in 70 Danish patients with idiopathic haemochromatosis.

[^]
57.

Edwards CQ et. al. (1988) Prevalence of hemochromatosis among 11,065 presumably healthy blood donors.

[^]
58.

Edwards CQ et. al. (1986) Mapping the locus for hereditary hemochromatosis: localization between HLA-B and HLA-A.

[^]
59.

Simon M et. al. (1987) A study of 609 HLA haplotypes marking for the hemochromatosis gene: (1) mapping of the gene near the HLA-A locus and characters required to define a heterozygous population and (2) hypothesis concerning the underlying cause of hemochromatosis-HLA association.

[^]
60.

Powell LW et. al. (1987) Genetic hemochromatosis and HLA linkage.

[^]
61.

Eriksson S et. al. (1986) A Swedish family with alpha 1-antitrypsin deficiency, haemochromatosis, haemoglobinopathy D and early death in liver cirrhosis.

[^]
62.

Siemons LJ et. al. (1987) Hypogonadotropic hypogonadism in hemochromatosis: recovery of reproductive function after iron depletion.

[^]
63.

Escobar GJ et. al. (1987) Primary hemochromatosis in childhood.

[^]
64.

Niederau C et. al. (1985) Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis.

[^]
65.

MacSween RN et. al. (1973) Hepatic cirrhosis: a clinico-pathological review of 520 cases.

[^]
66.

Saddi R et. al. (1974) Idiopathic haemochromatosis: an autosomal recessive disease.

[^]
67.

Balcerzak SP et. al. (1966) Idiopathic hemochromatosis. A study of three families.

[^]
68.

Charlton RW et. al. (1967) Idiopathic hemochromatosis in young subjects. Clinical, pathological, and chemical findings in four patients.

[^]
69.

Felts JH et. al. (1967) Hemochromatosis in two young sisters. Case studies and a family survey.

[^]
70.

Cazzola M et. al. (1983) Juvenile idiopathic haemochromatosis: a life-threatening disorder presenting as hypogonadotropic hypogonadism.

[^]
71.

Ritter B et. al. (1984) HLA as a marker of the hemochromatosis gene in Sweden.

[^]
72.

Le Mignon L et. al. (1983) An HLA-All association with the hemochromatosis allele?

[^]
73.

Anand S et. al. () Idiopathic hemochromotosis and alpha-1-antitrypsin deficiency: coexistence in a family with progressive liver disease in the proband.

[^]
74.

Olsson KS et. al. (1984) Screening for iron overload using transferrin saturation.

[^]
75.

Muir WA et. al. (1984) Evidence for heterogeneity in hereditary hemochromatosis. Evaluation of 174 persons in nine families.

[^]
76.

Olsson KS et. al. (1983) Prevalence of iron overload in central Sweden.

[^]
77.

Dadone MM et. al. (1982) Hereditary hemochromatosis. Analysis of laboratory expression of the disease by genotype in 18 pedigrees.

[^]
78.

Bassett ML et. al. (1982) Idiopathic hemochromatosis: demonstration of homozygous-heterozygous mating by HLA typing of families.

[^]
79.

None (1982) A foundation for hemochromatosis.

[^]
80.

Edwards CQ et. al. (1981) Hereditary hemochromatosis: contributions of genetic analyses.

[^]
81.

Simon M et. al. (1980) Idiopathic hemochromatosis: a study of biochemical expression in 247 heterozygous members of 63 families: evidence for a single major HLA-linked gene.

[^]
82.

Beaumont C et. al. (1980) Hepatic and serum ferritin concentrations in patients with idiopathic hemochromatosis.

[^]
83.

Valberg LS et. al. (1980) Clinical and biochemical expression of the genetic abnormality in idiopathic hemochromatosis.

[^]
84.

Edwards CQ et. al. (1980) Homozygosity for hemochromatosis: clinical manifestations.

[^]
85.

Cutler DJ et. al. (1980) Hemochromatosis heart disease: an unemphasized cause of potentially reversible restrictive cardiomyopathy.

[^]
86.

Elzouki AN et. al. (1995) Increased PiZ gene frequency for alpha 1 antitrypsin in patients with genetic haemochromatosis.

[^]
87.

Hashimoto K et. al. (1995) A gene outside the human MHC related to classical HLA class I genes.

[^]
88.

Calandro LM et. al. (1995) Characterization of a recombinant that locates the hereditary hemochromatosis gene telomeric to HLA-F.

[^]
89.

Jazwinska EC et. al. (1995) Haplotype analysis in Australian hemochromatosis patients: evidence for a predominant ancestral haplotype exclusively associated with hemochromatosis.

[^]
90.

Barton JC et. al. (1994) Blood lead concentrations in hereditary hemochromatosis.

[^]
91.

None () A prevalence and fertility study of haemochromatosis in Saguenay-Lac-Saint-Jean.

[^]
92.

Jazwinska EC et. al. (1993) Localization of the hemochromatosis gene close to D6S105.

[^]
93.

Deugnier YM et. al. (1993) Primary liver cancer in genetic hemochromatosis: a clinical, pathological, and pathogenetic study of 54 cases.

[^]
94.

Raha-Chowdhury R et. al. (1996) A new highly polymorphic marker in the 5' untranslated region of HLA-F shows strong allelic association with haemochromatosis.

[^]
95.

Rothenberg BE et. al. (1996) beta2 knockout mice develop parenchymal iron overload: A putative role for class I genes of the major histocompatibility complex in iron metabolism.

[^]
96.

None (1996) Haemochromatosis: strike while the iron is hot.

[^]
97.

Feder JN et. al. (1996) A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis.

[^]
98.

Jazwinska EC et. al. (1996) Haemochromatosis and HLA-H.

[^]
99.

Jouanolle AM et. al. (1996) Haemochromatosis and HLA-H.

[^]
100.

Bulaj ZJ et. al. (1996) Clinical and biochemical abnormalities in people heterozygous for hemochromatosis.

[^]
101.

Robson KJ et. al. (1997) Haemochromatosis: a gene at last?

[^]
102.

Carella M et. al. (1997) Mutation analysis of the HLA-H gene in Italian hemochromatosis patients.

[^]
103.

Beutler E et. al. (1997) HLA-H mutations in the Ashkenazi Jewish population.

[^]
104.

Beutler E et. al. (1997) HLA-H and associated proteins in patients with hemochromatosis.

[^]
105.

None (1997) The significance of the 187G (H63D) mutation in hemochromatosis.

[^]
106.

Beckman LE et. al. () Ethnic differences in the HFE codon 282 (Cys/Tyr) polymorphism.

[^]
107.

Parkkila S et. al. (1997) Association of the transferrin receptor in human placenta with HFE, the protein defective in hereditary hemochromatosis.

[^]
108.

None (1997) Haemochromatosis, HFE and genetic complexity.

[^]
109.

None (1998) Targeted disruption of the HFE gene.

[^]
110.

Zhou XY et. al. (1998) HFE gene knockout produces mouse model of hereditary hemochromatosis.

[^]
111.

Lalouel JM et. al. (1985) Genetic analysis of idiopathic hemochromatosis using both qualitative (disease status) and quantitative (serum iron) information.

[^]
112.

Piperno A et. al. (1998) Heterogeneity of hemochromatosis in Italy.

[^]
113.

Pérez Roldán F et. al. (1998) Hemochromatosis presenting as acute liver failure after iron supplementation.

[^]
114.

Lonjou C et. al. (1998) Allelic association under map error and recombinational heterogeneity: a tale of two sites.

[^]
115.

Burt MJ et. al. (1998) The significance of haemochromatosis gene mutations in the general population: implications for screening.

[^]
116.

Powell LW et. al. (1998) Diagnosis of hemochromatosis.

[^]
117.

Barton JC et. al. (1998) Management of hemochromatosis. Hemochromatosis Management Working Group.

[^]
118.

Looker AC et. al. (1998) Prevalence of elevated serum transferrin saturation in adults in the United States.

[^]
119.

Phatak PD et. al. (1998) Prevalence of hereditary hemochromatosis in 16031 primary care patients.

[^]
120.

Brittenham GM et. al. (1998) Research priorities in hereditary hemochromatosis.

[^]
121.

Waheed A et. al. (1999) Association of HFE protein with transferrin receptor in crypt enterocytes of human duodenum.

[^]
122.

Fleming RE et. al. (1999) Mechanism of increased iron absorption in murine model of hereditary hemochromatosis: increased duodenal expression of the iron transporter DMT1.

[^]
123.

Roy CN et. al. (1999) The hereditary hemochromatosis protein, HFE, specifically regulates transferrin-mediated iron uptake in HeLa cells.

[^]
124.

Rochette J et. al. (1999) Multicentric origin of hemochromatosis gene (HFE) mutations.

[^]
125.

Merryweather-Clarke AT et. al. (1999) A retrospective anonymous pilot study in screening newborns for HFE mutations in Scandinavian populations.

[^]
126.

Grove J et. al. (1998) Heterozygotes for HFE mutations have no increased risk of advanced alcoholic liver disease.

[^]
127.

Zoller H et. al. (1999) Duodenal metal-transporter (DMT-1, NRAMP-2) expression in patients with hereditary haemochromatosis.

[^]
128.

Olynyk JK et. al. (1999) A population-based study of the clinical expression of the hemochromatosis gene.

[^]
129.

Bahram S et. al. (1999) Experimental hemochromatosis due to MHC class I HFE deficiency: immune status and iron metabolism.

[^]
130.

Willis G et. al. (2000) Incidence of liver disease in people with HFE mutations.

[^]
131.

Hickman PE et. al. (2000) Automated measurement of unsaturated iron binding capacity is an effective screening strategy for C282Y homozygous haemochromatosis.

[^]
132.

Griffiths W et. al. (2000) Haemochromatosis: novel gene discovery and the molecular pathophysiology of iron metabolism.

[^]
133.

Hussain SP et. al. (2000) Increased p53 mutation load in nontumorous human liver of wilson disease and hemochromatosis: oxyradical overload diseases.

[^]
134.

Bulaj ZJ et. al. (2000) Disease-related conditions in relatives of patients with hemochromatosis.

[^]
135.

Fleming RE et. al. (2001) Mouse strain differences determine severity of iron accumulation in Hfe knockout model of hereditary hemochromatosis.

[^]
136.

Brown AS et. al. () Hemochromatosis-associated morbidity in the United States: an analysis of the National Hospital Discharge Survey, 1979-1997.

[^]
137.

Sproule TJ et. al. (2001) Naturally variant autosomal and sex-linked loci determine the severity of iron overload in beta 2-microglobulin-deficient mice.

[^]
138.

Steinberg KK et. al. (2001) Prevalence of C282Y and H63D mutations in the hemochromatosis (HFE) gene in the United States.

[^]
139.

Barton JC et. al. () Diagnosis of hemochromatosis in family members of probands: a comparison of phenotyping and HFE genotyping.

[^]
140.

Pozzato G et. al. (2001) Haemochromatosis gene mutations in a clustered Italian population: evidence of high prevalence in people of Celtic ancestry.

[^]
141.

Cairo G et. al. (2001) Reduced serum ceruloplasmin levels in hereditary haemochromatosis.

[^]
142.

Barton JC et. al. () Inheritance of two HFE mutations in African Americans: cases with hemochromatosis phenotypes and estimates of hemochromatosis phenotype frequency.

[^]
143.

Mura C et. al. (2001) Variation of iron loading expression in C282Y homozygous haemochromatosis probands and sib pairs.

[^]
144.

Roy CN et. al. (2001) Recent advances in disorders of iron metabolism: mutations, mechanisms and modifiers.

[^]
145.

de Juan D et. al. (2001) HFE gene mutations analysis in Basque hereditary haemochromatosis patients and controls.

[^]
146.

Townsend A et. al. (2002) Role of HFE in iron metabolism, hereditary haemochromatosis, anaemia of chronic disease, and secondary iron overload.

[^]
147.

Trinder D et. al. (2002) Iron uptake from plasma transferrin by the duodenum is impaired in the Hfe knockout mouse.

[^]
148.

Hofmann WK et. al. (2002) Mutation analysis of transferrin-receptor 2 in patients with atypical hemochromatosis.

[^]
149.

Nicolas G et. al. (2003) Constitutive hepcidin expression prevents iron overload in a mouse model of hemochromatosis.

[^]
150.

Muckenthaler M et. al. (2003) Regulatory defects in liver and intestine implicate abnormal hepcidin and Cybrd1 expression in mouse hemochromatosis.

[^]
151.

Halsall DJ et. al. (2003) Typical type 2 diabetes mellitus and HFE gene mutations: a population-based case - control study.

[^]
152.

Milman N et. al. (2003) Evidence that the Cys282Tyr mutation of the HFE gene originated from a population in Southern Scandinavia and spread with the Vikings.

[^]
153.

Merryweather-Clarke AT et. al. (2003) Digenic inheritance of mutations in HAMP and HFE results in different types of haemochromatosis.

[^]
154.

NUSSBAUMER T et. al. (1952) [Juvenile hemochromatosis in three sisters and one brother associated with consanguinity of the parents; anatomo-clinical and genetic study of the endocrino-hepato-myocardial syndrome].

[^]
155.

DEBRE R et. al. (1958) Genetics of haemochromatosis.

[^]
156.

BOTHWELL TH et. al. (1959) A familial study in idiopathic hemochromatosis.

[^]
157.

PERKINS KW et. al. (1965) IDIOPATHIC HAEMOCHROMATOSIS IN CHILDREN; REPORT OF A FAMILY.

[^]
158.

JOHNSON GB et. al. (1962) Familial aspects of idiopathic hemochromatosis.

[^]
159.

Roy CN et. al. (2004) An Hfe-dependent pathway mediates hyposideremia in response to lipopolysaccharide-induced inflammation in mice.

[^]
160.

None (2004) Hereditary hemochromatosis--a new look at an old disease.

[^]
161.

Le Gac G et. al. (2004) The recently identified type 2A juvenile haemochromatosis gene (HJV), a second candidate modifier of the C282Y homozygous phenotype.

[^]
162.

Distante S et. al. (2004) The origin and spread of the HFE-C282Y haemochromatosis mutation.

[^]
163.

Lee PL et. al. (2004) Hemojuvelin (HJV) mutations in persons of European, African-American and Asian ancestry with adult onset haemochromatosis.

[^]
164.

Valenti L et. al. (2004) The mitochondrial superoxide dismutase A16V polymorphism in the cardiomyopathy associated with hereditary haemochromatosis.

[^]
165.

McDermott JH et. al. (2005) Hypogonadism in hereditary hemochromatosis.

[^]
166.

Drakesmith H et. al. (2005) HIV-1 Nef down-regulates the hemochromatosis protein HFE, manipulating cellular iron homeostasis.

[^]
167.

Matas M et. al. (2006) Prevalence of HFE C282Y and H63D in Jewish populations and clinical implications of H63D homozygosity.

[^]
168.

Barton JC et. al. (2006) Initial screening transferrin saturation values, serum ferritin concentrations, and HFE genotypes in Native Americans and whites in the Hemochromatosis and Iron Overload Screening Study.

[^]
169.

Ludwiczek S et. al. (2007) Ca2+ channel blockers reverse iron overload by a new mechanism via divalent metal transporter-1.

[^]
170.

Adams PC et. al. (2007) Haemochromatosis.

[^]
171.

Le Gac G et. al. (2008) Homozygous deletion of HFE produces a phenotype similar to the HFE p.C282Y/p.C282Y genotype.

[^]
172.

Thomas GR et. al. (1995) The Wilson disease gene: spectrum of mutations and their consequences.

[^]
173.

Thomas GR et. al. (1995) Wilson disease in Iceland: a clinical and genetic study.

[^]
174.

Thomas GR et. al. (1995) Haplotypes and mutations in Wilson disease.

[^]
175.

Sasaki N et. al. (1994) The gene responsible for LEC hepatitis, located on rat chromosome 16, is the homolog to the human Wilson disease gene.

[^]
176.

Bull PC et. al. (1993) The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene.

[^]
177.

Tanzi RE et. al. (1993) The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene.

[^]
178.

Figus A et. al. (1995) Molecular pathology and haplotype analysis of Wilson disease in Mediterranean populations.

[^]
179.

Terada K et. al. (1998) Restoration of holoceruloplasmin synthesis in LEC rat after infusion of recombinant adenovirus bearing WND cDNA.

[^]
180.

Kim EK et. al. (1998) Identification of three novel mutations and a high frequency of the Arg778Leu mutation in Korean patients with Wilson disease.

[^]
181.

Loudianos G et. al. (1998) Further delineation of the molecular pathology of Wilson disease in the Mediterranean population.

[^]
182.

Duc HH et. al. () His1069Gln and six novel Wilson disease mutations: analysis of relevance for early diagnosis and phenotype.

[^]
183.

Loudianos G et. al. (1999) Molecular characterization of wilson disease in the Sardinian population--evidence of a founder effect.

[^]
184.

Okada T et. al. (2000) Mutational analysis of ATP7B and genotype-phenotype correlation in Japanese with Wilson's disease.

[^]
185.

Forbes JR et. al. (2000) Copper-dependent trafficking of Wilson disease mutant ATP7B proteins.

[^]
186.

García-Villarreal L et. al. (2000) High prevalence of the very rare Wilson disease gene mutation Leu708Pro in the Island of Gran Canaria (Canary Islands, Spain): a genetic and clinical study.

[^]
187.

Takeshita Y et. al. (2002) Two families with Wilson disease in which siblings showed different phenotypes.

[^]
188.

Margarit E et. al. (2005) Mutation analysis of Wilson disease in the Spanish population -- identification of a prevalent substitution and eight novel mutations in the ATP7B gene.

[^]
189.

Gupta A et. al. (2005) Molecular pathogenesis of Wilson disease: haplotype analysis, detection of prevalent mutations and genotype-phenotype correlation in Indian patients.

[^]
190.

Gromadzka G et. al. (2005) Frameshift and nonsense mutations in the gene for ATPase7B are associated with severe impairment of copper metabolism and with an early clinical manifestation of Wilson's disease.

[^]
191.

Park S et. al. (2007) Identification of novel ATP7B gene mutations and their functional roles in Korean patients with Wilson disease.

[^]
192.

Park HD et. al. (2009) Carrier frequency of the R778L, A874V, and N1270S mutations in the ATP7B gene in a Korean population.

[^]
193.

Wang LH et. al. (2011) Mutation analysis of 73 southern Chinese Wilson's disease patients: identification of 10 novel mutations and its clinical correlation.

[^]
194.

None (1978) Diagnosis of treatable Wilson's disease.

[^]
195.

Gibbs K et. al. (1979) A study of the caeruloplasmin concentrations found in 75 patients with Wilson's disease, their kinships and various control groups.

[^]
196.

Wiebers DO et. al. (1979) Renal stones in Wilson's disease.

[^]
197.

Frommer D et. al. (1977) Kayser-Fleischer-like rings in patients without Wilson's disease.

[^]
198.

Dobyns WB et. al. (1979) Clinical spectrum of Wilson's disease (hepatolenticular degeneration).

[^]
199.

Passwell J et. al. (1977) Heterogeneity of Wilson's disease in Israel.

[^]
200.

Fitzgerald MA et. al. (1975) Wilson's disease (hepatolenticular degeneration) of late adult onset: report of case.

[^]
201.

Cossu P et. al. (1992) Prenatal diagnosis of Wilson's disease by analysis of DNA polymorphism.

[^]
202.

Scheffer H et. al. (1992) Identification of crossovers in Wilson disease families as reference points for a genetic localization of the gene.

[^]
203.

Li Y et. al. (1991) Spontaneous hepatic copper accumulation in Long-Evans Cinnamon rats with hereditary hepatitis. A model of Wilson's disease.

[^]
204.

Houwen RH et. al. (1990) Close linkage of the Wilson's disease locus to D13S12 in the chromosomal region 13q21 and not to ESD in 13q14.

[^]
205.

Bonné-Tamir B et. al. (1990) Wilson's disease in Israel: a genetic and epidemiological study.

[^]
206.

Danks DM et. al. (1990) Wilson's disease in adults with cirrhosis but no neurological abnormalities.

[^]
207.

Figus A et. al. (1989) Carrier detection and early diagnosis of Wilson's disease by restriction fragment length polymorphism analysis.

[^]
208.

Azizi E et. al. (1989) Hypercalciuria and nephrolithiasis as a presenting sign in Wilson disease.

[^]
209.

None (1988) Wilson's disease: yesterday, today, and tomorrow.

[^]
210.

None (1988) Remembering Kinnier Wilson.

[^]
211.

None (1988) Memories of my father [Kinnier Wilson].

[^]
212.

Yuzbasiyan-Gurkan V et. al. (1988) Linkage of the Wilson disease gene to chromosome 13 in North-American pedigrees.

[^]
213.

Farrer LA et. al. (1988) Predicting genotypes at loci for autosomal recessive disorders using linked genetic markers: application to Wilson's disease.

[^]
214.

Bowcock AM et. al. (1988) Eight closely linked loci place the Wilson disease locus within 13q14-q21.

[^]
215.

Polson RJ et. al. (1987) Reversal of severe neurological manifestations of Wilson's disease following orthotopic liver transplantation.

[^]
216.

Brewer GJ et. al. (1987) Treatment of Wilson's disease.

[^]
217.

Menerey KA et. al. (1988) The arthropathy of Wilson's disease: clinical and pathologic features.

[^]
218.

Bonné-Tamir B et. al. (1986) Evidence for linkage between Wilson disease and esterase D in three kindreds: detection of linkage for an autosomal recessive disorder by the family study method.

[^]
219.

Lingam S et. al. (1987) Neurological abnormalities in Wilson's disease are reversible.

[^]
220.

Czaja MJ et. al. (1987) Molecular studies of ceruloplasmin deficiency in Wilson's disease.

[^]
221.

Starosta-Rubinstein S et. al. (1987) Clinical assessment of 31 patients with Wilson's disease. Correlations with structural changes on magnetic resonance imaging.

[^]
222.

None (1987) Cardiac Wilson's disease.

[^]
223.

Frydman M et. al. (1985) Assignment of the gene for Wilson disease to chromosome 13: linkage to the esterase D locus.

[^]
224.

Sokol RJ et. al. (1985) Orthotopic liver transplantation for acute fulminant Wilson disease.

[^]
225.

Ross ME et. al. (1985) Late-onset Wilson's disease with neurological involvement in the absence of Kayser-Fleischer rings.

[^]
226.

Levi AJ et. al. (1967) Presymptomatic Wilson's disease.

[^]
227.

Strickland GT et. al. (1973) Wilson's disease in the United Kingdom and Taiwan. I. General characteristics of 142 cases and prognosis. II. A genetic analysis of 88 cases.

[^]
228.

Shokeir MH et. al. (1969) Cytochrome oxidase deficiency in Wilson's disease: a suggested ceruloplasmin function.

[^]
229.

None (1971) Investigations on the nature of ceruloplasmin deficiency in the newborn.

[^]
230.

Sternlieb I et. al. (1972) Chronic hepatitis as a first manifestation of Wilson's disease.

[^]
231.

Cox DW et. al. (1972) A genetic study of Wilson's disease: evidence for heterogeneity.

[^]
232.

Slovis TL et. al. (1971) The varied manifestations of Wilson's disease.

[^]
233.

Goldstein NP et. al. (1971) Wilson's disease (hepatolenticular degeneration). Treatment with penicillamine and changes in hepatic trapping of radioactive copper.

[^]
234.

Whelton MJ et. al. (1968) Azure lunules in Argyria. Corneal changes resembling Kayser-Fleischer Rings.

[^]
235.

Holtzman NA et. al. (1967) Ceruloplasmin in Wilson's disease.

[^]
236.

Hoogenraad TU et. al. (1983) 3 years of continuous oral zinc therapy in 4 patients with Wilson's disease.

[^]
237.

None (1983) Evaluation of segregation ratio in Wilson's disease.

[^]
238.

Carpenter TO et. al. (1983) Hypoparathyroidism in Wilson's disease.

[^]
239.

Owen CA et. al. (1982) Inherited copper toxicosis in Bedlington terriers: Wilson's disease (hepatolenticular degeneration).

[^]
240.

Factor SM et. al. (1982) The cardiomyopathy of Wilson's disease. Myocardial alterations in nine cases.

[^]
241.

Członkowska A et. al. (1981) Late onset of Wilson's disease. Report of a family.

[^]
242.

Hartard C et. al. (1994) Pregnancy in a patient with Wilson's disease treated with D-penicillamine and zinc sulfate. A case report and review of the literature.

[^]
243.

Devesa R et. al. (1995) Wilson's disease treated with trientine during pregnancy.

[^]
244.

None (1994) Dangers of interrupting decoppering treatment in Wilson's disease.

[^]
245.

Wu J et. al. (1994) The LEC rat has a deletion in the copper transporting ATPase gene homologous to the Wilson disease gene.

[^]
246.

Brewer GJ et. al. (1994) Treatment of Wilson's disease with zinc. XIII: Therapy with zinc in presymptomatic patients from the time of diagnosis.

[^]
247.

Thomas GR et. al. (1994) Haplotype studies in Wilson disease.

[^]
248.

Lang CJ et. al. (1993) Fatal deterioration of Wilson's disease after institution of oral zinc therapy.

[^]
249.

Hoppe B et. al. (1993) Hypercalciuria and nephrocalcinosis, a feature of Wilson's disease.

[^]
250.

Petrukhin K et. al. (1993) Mapping, cloning and genetic characterization of the region containing the Wilson disease gene.

[^]
251.

Kooy RF et. al. (1993) Physical localisation of the chromosomal marker D13S31 places the Wilson disease locus at the junction of bands q14.3 and q21.1 of chromosome 13.

[^]
252.

Yuzbasiyan-Gurkan V et. al. (1993) Linkage studies of the esterase D and retinoblastoma genes to canine copper toxicosis: a model for Wilson disease.

[^]
253.

van Wassenaer-van Hall HN et. al. () Cranial MR in Wilson disease: abnormal white matter in extrapyramidal and pyramidal tracts.

[^]
254.

Guarino M et. al. (1995) No neurological improvement after liver transplantation for Wilson's disease.

[^]
255.

Theophilos MB et. al. (1996) The toxic milk mouse is a murine model of Wilson disease.

[^]
256.

Kuo YM et. al. (1997) Developmental expression of the mouse mottled and toxic milk genes suggests distinct functions for the Menkes and Wilson disease copper transporters.

[^]
257.

Huang L et. al. (1997) A novel gene involved in zinc transport is deficient in the lethal milk mouse.

[^]
258.

Brewer GJ et. al. (1998) Treatment of Wilson's disease with zinc: XV long-term follow-up studies.

[^]
259.

van de Sluis BJ et. al. (1999) Genetic mapping of the copper toxicosis locus in Bedlington terriers to dog chromosome 10, in a region syntenic to human chromosome region 2p13-p16.

[^]
260.

Chowrimootoo GF et. al. (1998) Caeruloplasmin isoforms in Wilson's disease in neonates.

[^]
261.

Ferlan-Marolt V et. al. (1999) Fulminant Wilsonian hepatitis unmasked by disease progression: report of a case and review of the literature.

[^]
262.

None (1999) Penicillamine: the treatment of first choice for patients with Wilson's disease.

[^]
263.

None (1999) Penicillamine should not be used as initial therapy in Wilson's disease.

[^]
264.

None (1999) Penicillamine as a controversial treatment for Wilson's disease.

[^]
265.

Buiakova OI et. al. (1999) Null mutation of the murine ATP7B (Wilson disease) gene results in intracellular copper accumulation and late-onset hepatic nodular transformation.

[^]
266.

Gow PJ et. al. (2000) Diagnosis of Wilson's disease: an experience over three decades.

[^]
267.

Gu M et. al. (2000) Oxidative-phosphorylation defects in liver of patients with Wilson's disease.

[^]
268.

Firneisz G et. al. (2001) Postcremation diagnosis from an electric shaver.

[^]
269.

None (2001) Postcremation diagnosis.

[^]
270.

None (2001) Postcremation diagnosis.

[^]
271.

Olivarez L et. al. (2001) Estimate of the frequency of Wilson's disease in the US Caucasian population: a mutation analysis approach.

[^]
272.

Hedera P et. al. (2002) White matter changes in Wilson disease.

[^]
273.

Hlubocká Z et. al. (2002) Cardiac involvement in Wilson disease.

[^]
274.

Brewer GJ et. al. (2003) Treatment of Wilson disease with ammonium tetrathiomolybdate: III. Initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy.

[^]
275.

Wu ZY et. al. (2003) Molecular diagnosis and prophylactic therapy for presymptomatic Chinese patients with Wilson disease.

[^]
276.

None (1956) Penicillamine, a new oral therapy for Wilson's disease.

[^]
277.

None (1960) A genetical analysis of thirty families with Wilson's disease (hepatolenticular degeneration).

[^]
278.

LITIN RB et. al. (1959) Hypercalciuria in hepatolenticular degeneration (Wilson's disease).

[^]
279.

Jung KH et. al. (2005) Wilson disease with an initial manifestation of polyneuropathy.

[^]
280.

Brewer GJ et. al. (2006) Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease.

[^]
281.

None (2006) Regional distribution of mutations of the ATP7B gene in patients with Wilson disease: impact on genetic testing.

[^]
282.

Lang PA et. al. (2007) Liver cell death and anemia in Wilson disease involve acid sphingomyelinase and ceramide.

[^]
283.

de Bie P et. al. (2007) Molecular pathogenesis of Wilson and Menkes disease: correlation of mutations with molecular defects and disease phenotypes.

[^]
284.

Mak CM et. al. (2008) Mutational analysis of 65 Wilson disease patients in Hong Kong Chinese: identification of 17 novel mutations and its genetic heterogeneity.

[^]
285.

Alvarez HM et. al. (2010) Tetrathiomolybdate inhibits copper trafficking proteins through metal cluster formation.

[^]
286.

Adeva M et al. (2006) Clinical and molecular characterization defines a broadened spectrum of autosomal recessive polycystic kidney disease (ARPKD).

[^]
287.

CAROLI J et al. (1958) [Congenital polycystic dilation of the intrahepatic bile ducts; attempt at classification].

[^]
288.

Turnberg LA et al. (1968) Biliary secretion in a patient with cystic dilation of the intrahepatic biliary tree.

[^]
289.

Hunter FM et al. (1966) Congenital dilation of the intrahepatic bile ducts.

[^]
290.

Germain DP et al. (1999) Fabry disease: identification of novel alpha-galactosidase A mutations and molecular carrier detection by use of fluorescent chemical cleavage of mismatches.

[^]
291.

Ohshima T et al. (1999) Aging accentuates and bone marrow transplantation ameliorates metabolic defects in Fabry disease mice.

[^]
292.

Schiffmann R et al. (2000) Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease.

[^]
293.

Takenaka T et al. (2000) Long-term enzyme correction and lipid reduction in multiple organs of primary and secondary transplanted Fabry mice receiving transduced bone marrow cells.

[^]
294.

Asano N et al. (2000) In vitro inhibition and intracellular enhancement of lysosomal alpha-galactosidase A activity in Fabry lymphoblasts by 1-deoxygalactonojirimycin and its derivatives.

[^]
295.

Brady RO et al. (2000) Clinical features of and recent advances in therapy for Fabry disease.

[^]
296.

Ioannou YA et al. (2001) Fabry disease: preclinical studies demonstrate the effectiveness of alpha-galactosidase A replacement in enzyme-deficient mice.

[^]
297.

Prigozy TI et al. (2001) Glycolipid antigen processing for presentation by CD1d molecules.

[^]
298.

Eng CM et al. (2001) A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies.

[^]
299.

Jung SC et al. (2001) Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice.

[^]
300.

Qin G et al. (2001) Preselective gene therapy for Fabry disease.

[^]
301.

Schiffmann R et al. (2001) Enzyme replacement therapy in Fabry disease: a randomized controlled trial.

[^]
302.

Pastores GM et al. (2001) Enzyme-replacement therapy for Anderson-Fabry disease.

[^]
303.

Germain DP et al. (2001) Co-occurrence and contribution of Fabry disease and Klippel-Trénaunay-Weber syndrome to a patient with atypical skin lesions.

[^]
304.

MacDermot KD et al. (2001) Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males.

[^]
305.

MacDermot KD et al. (2001) Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females.

[^]
306.

Whybra C et al. (2001) Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes.

[^]
307.

Branton MH et al. (2002) Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course.

[^]
308.

Romeo G et al. (1972) Genetic heterogeneity of alpha-galactosidase in fabry's disease.

[^]
309.

Heltianu C et al. (2002) Endothelial nitric oxide synthase gene polymorphisms in Fabry's disease.

[^]
310.

Takahashi H et al. (2002) Long-term systemic therapy of Fabry disease in a knockout mouse by adeno-associated virus-mediated muscle-directed gene transfer.

[^]
311.

Germain DP et al. (2002) Patients affected with Fabry disease have an increased incidence of progressive hearing loss and sudden deafness: an investigation of twenty-two hemizygous male patients.

[^]
312.

Blom D et al. (2003) Recombinant enzyme therapy for Fabry disease: absence of editing of human alpha-galactosidase A mRNA.

[^]
313.

Senechal M et al. (2003) Fabry disease: a functional and anatomical study of cardiac manifestations in 20 hemizygous male patients.

[^]
314.

Waldek S et al. (2003) PR interval and the response to enzyme-replacement therapy for Fabry's disease.

[^]
315.

Nakao S et al. (2003) Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype.

[^]
316.

WISE D et al. (1962) Angiokeratoma corporis diffusum. A clinical study of eight affected families.

[^]
317.

SWEELEY CC et al. (1963) FABRY'S DISEASE: CLASSIFICATION AS A SPHINGOLIPIDOSIS AND PARTIAL CHARACTERIZATION OF A NOVEL GLYCOLIPID.

[^]
318.

HAMBURGER J et al. (1964) [ON AN UNUSUAL FAMILIAL MALFORMATION OF THE RENAL EPITHELIUM].

[^]
319.

RAHMAN AN et al. (1961) Angiokeratoma corporis diffusum universale (hereditary dystopic lipidosis).

[^]
320.

Wilcox WR et al. (2004) Long-term safety and efficacy of enzyme replacement therapy for Fabry disease.

[^]
321.

Verovnik F et al. (2004) Remarkable variability in renal disease in a large Slovenian family with Fabry disease.

[^]
322.

Spinelli L et al. (2004) Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease.

[^]
323.

Germain DP et al. (2005) Osteopenia and osteoporosis: previously unrecognized manifestations of Fabry disease.

[^]
324.

Rolfs A et al. (2005) Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study.

[^]
325.

Prüss H et al. (2006) Paroxysmal vertigo as the presenting symptom of Fabry disease.

[^]
326.

Nagao Y et al. (1991) Hypertrophic cardiomyopathy in late-onset variant of Fabry disease with high residual activity of alpha-galactosidase A.

[^]
327.

Nance CS et al. (2006) Later-onset Fabry disease: an adult variant presenting with the cramp-fasciculation syndrome.

[^]
328.

Mastropasqua L et al. (2006) Corneal and conjunctival manifestations in Fabry disease: in vivo confocal microscopy study.

[^]
329.

Spada M et al. (2006) High incidence of later-onset fabry disease revealed by newborn screening.

[^]
330.

Kirkilionis AJ et al. (1991) Fabry disease in a large Nova Scotia kindred: carrier detection using leucocyte alpha-galactosidase activity and an NcoI polymorphism detected by an alpha-galactosidase cDNA clone.

[^]
331.

Faggiano A et al. (2006) Endocrine dysfunction in patients with Fabry disease.

[^]
332.

Eng CM et al. (2006) Fabry disease: guidelines for the evaluation and management of multi-organ system involvement.

[^]
333.

Kaneski CR et al. (2006) Myeloperoxidase predicts risk of vasculopathic events in hemizgygous males with Fabry disease.

[^]
334.

Wang RY et al. (2007) Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life.

[^]
335.

Kim W et al. (2007) Pulmonary manifestations of Fabry disease and positive response to enzyme replacement therapy.

[^]
336.

Moore DF et al. (2007) The cerebral vasculopathy of Fabry disease.

[^]
337.

Clarke JT et al. (2007) Narrative review: Fabry disease.

[^]
338.

Opitz JM et al. (1965) The Genetics of Angiokeratoma Corporis Diffusum (Fabry's Disease) and Its Linkage Relations with the Xg Locus.

[^]
339.

Auray-Blais C et al. (2008) Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease.

[^]
340.

Aerts JM et al. (2008) Elevated globotriaosylsphingosine is a hallmark of Fabry disease.

[^]
341.

von Scheidt W et al. (1991) An atypical variant of Fabry's disease with manifestations confined to the myocardium.

[^]
342.

Fellgiebel A et al. (2009) Diagnostic utility of different MRI and MR angiography measures in Fabry disease.

[^]
343.

Mehta A et al. (2009) Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey.

[^]
344.

Waldek S et al. (2009) Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry.

[^]
345.

Tajima Y et al. (2009) Use of a modified alpha-N-acetylgalactosaminidase in the development of enzyme replacement therapy for Fabry disease.

[^]
346.

Crosbie TW et al. (2009) Psychological aspects of patients with Fabry disease.

[^]
347.

Testai FD et al. (2010) Inherited metabolic disorders and stroke part 1: Fabry disease and mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes.

[^]
348.

GRUBER M et al. () [Not Available].

[^]
349.

GRUBER M et al. (1946) [Not Available].

[^]
350.

Beaudet AL et al. (1978) Detection of Fabry's disease heterozygotes by hair root analysis.

[^]
351.

Ogawa K et al. (1990) Restricted accumulation of globotriaosylceramide in the hearts of atypical cases of Fabry's disease.

[^]
352.

Kornreich R et al. (1990) Alpha-galactosidase A gene rearrangements causing Fabry disease. Identification of short direct repeats at breakpoints in an Alu-rich gene.

[^]
353.

Hasholt L et al. (1990) A Fabry's disease heterozygote with a new mutation: biochemical, ultrastructural, and clinical investigations.

[^]
354.

Bird TD et al. (1978) Neurological manifestations of Fabry disease in female carriers.

[^]
355.

Elleder M et al. (1990) Cardiocyte storage and hypertrophy as a sole manifestation of Fabry's disease. Report on a case simulating hypertrophic non-obstructive cardiomyopathy.

[^]
356.

Spence MW et al. (1978) Angiokeratoma corporis diffusum (Anderson-Fabry disease) in a single large family in Nova Scotia.

[^]
357.

Hamers MN et al. (1979) Relationship between biochemical and clinical features in an English Anderson-Fabry family.

[^]
358.

Bernstein HS et al. (1989) Fabry disease: six gene rearrangements and an exonic point mutation in the alpha-galactosidase gene.

[^]
359.

MacDermot KD et al. (1987) Anderson Fabry disease, a close linkage with highly polymorphic DNA markers DXS17, DXS87 and DXS88.

[^]
360.

Rodriguez FH et al. (1985) Fabry's disease in a heterozygous woman.

[^]
361.

Hasholt L et al. (1986) Lysosomal alpha-galactosidase in endothelial cell cultures established from a Fabry hemizygous and normal umbilical veins.

[^]
362.

Lemansky P et al. (1987) Synthesis and processing of alpha-galactosidase A in human fibroblasts. Evidence for different mutations in Fabry disease.

[^]
363.

Efthimiou J et al. (1986) Short PR intervals and tachyarrhythmias in Fabry's disease.

[^]
364.

Sakuraba H et al. (1986) Cardiovascular manifestations in Fabry's disease. A high incidence of mitral valve prolapse in hemizygotes and heterozygotes.

[^]
365.

Friedlaender MM et al. (1987) Renal biopsy in Fabry's disease eight years after successful renal transplantation.

[^]
366.

Mutoh T et al. (1988) Severe orthostatic hypotension in a female carrier of Fabry's disease.

[^]
367.

Ropers HH et al. (1977) Evidence for preferential X-chromosome inactivation in a family with Fabry disease.

[^]
368.

Peltier A et al. (1977) Pseudo-clinical Fabry's disease without alpha galactosidase deficiency.

[^]
369.

Loonen MC et al. (1974) Letter: Angiokeratoma corporis diffusum and lysosomal enzyme deficiency.

[^]
370.

Roudebush CP et al. (1973) The abbreviated PR interval of Fabry's disease.

[^]
371.

Mapes CA et al. (1970) Enzyme replacement in Fabry's disease, an inborn error of metabolism.

[^]
372.

Flynn DM et al. (1972) Gut lesions in Fabry's disease without a rash.

[^]
373.

Patel V et al. (1972) Deficiency of alpha-L-fucosidase.

[^]
374.

Johnston AW et al. (1969) Linkage relationships of the angiokeratoma (Fabry) locus.

[^]
375.

Kint JA et al. (1970) Fabry's disease: alpha-galactosidase deficiency.

[^]
376.

Romeo G et al. (1970) Genetic inactivation of the alpha-galactosidase locus in carriers of Fabry's disease.

[^]
377.

Clarke JT et al. (1971) Ceramide trihexosidosis (fabry's disease) without skin lesions.

[^]
378.

Philippart M et al. (1969) Urinary glycolipids in Fabry's disease. Their examination in the detection of atypical variants and the pre-symptomatic state.

[^]
379.

Franceschetti AT et al. (1969) A study of Fabry's disease. I. Clinical examination of a family with cornea verticillata.

[^]
380.

Frost P et al. (1966) Fabry's disease--glycolipid lipidosis. Histochemical and electron microscopic studies of two cases.

[^]
381.

Brady RO et al. (1967) Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency.

[^]
382.

Rosenberg DM et al. (1980) Chronic airflow obstruction in Fabry's disease.

[^]
383.

Broadbent JC et al. (1981) Fabry cardiomyopathy in the female confirmed by endomyocardial biopsy.

[^]
384.

Sheth KJ et al. (1981) Heterozygote detection in Fabry disease utilizing multiple enzyme activities.

[^]
385.

Johnston AW et al. (1981) Linkage relationship of the loci for Anderson--Fabry disease and the Xg blood groups.

[^]
386.

Cable WJ et al. (1982) Fabry disease: significance of ultrastructural localization of lipid inclusions in dermal nerves.

[^]
387.

Tagliavini F et al. (1982) Anderson-Fabry's disease: neuropathological and neurochemical investigation.

[^]
388.

Bach G et al. (1982) Pseudodeficiency of alpha-galactosidase A.

[^]
389.

Clement M et al. (1982) Renal transplantation in Anderson-Fabry disease.

[^]
390.

Cable WJ et al. (1982) Fabry disease: detection of heterozygotes by examination of glycolipids in urinary sediment.

[^]
391.

Bannwart F et al. (1982) [Fabry's disease. Light and electron microscopic cardiac findings 12 years after successful kidney transplantation].

[^]
392.

Friedman LS et al. (1984) Jejunal diverticulosis with perforation as a complication of Fabry's disease.

[^]
393.

Maisey DN et al. (1980) Basilar artery aneurysm and Anderson-Fabry disease.

[^]
394.

Sørensen SA et al. (1980) alpha-Galactosidase isozymes in normal individuals, and in Fabry hemizygotes and heterozygotes.

[^]
395.

Pyeritz RE et al. (1980) Plasma exchange removes glycosphingolipid in Fabry disease.

[^]
396.

Faraggiana T et al. (1981) Light- and electron-microscopic histochemistry of Fabry's disease.

[^]
397.

Cable WJ et al. (1982) Fabry disease: impaired autonomic function.

[^]
398.

Colucci WS et al. (1982) Hypertrophic obstructive cardiomyopathy due to Fabry's disease.

[^]
399.

Novo FJ et al. (1995) Editing of human alpha-galactosidase RNA resulting in a pyrimidine to purine conversion.

[^]
400.

Eng CM et al. (1993) Nature and frequency of mutations in the alpha-galactosidase A gene that cause Fabry disease.

[^]
401.

Nakao S et al. (1995) An atypical variant of Fabry's disease in men with left ventricular hypertrophy.

[^]
402.

Hillsley RE et al. (1995) Inherited restrictive cardiomyopathy in a 74-year-old woman: a case of Fabry's disease.

[^]
403.

Elleder M et al. (1994) Leptomeningeal lipid storage patterns in Fabry disease.

[^]
404.

Eng CM et al. (1994) Molecular basis of Fabry disease: mutations and polymorphisms in the human alpha-galactosidase A gene.

[^]
405.

Halsted CH et al. (1975) Letter: Occurrence of celiac sprue in a patient with Fabry's disease.

[^]
406.

Spence MW et al. (1976) Failure to correct the metabolic defect by renal allotransplantion in Fabry's disease.

[^]
407.

Pierides AM et al. (1976) Study on a family with anderson--Fabry's disease and associated familial spastic paraplegia.

[^]
408.

Davies JP et al. (1993) Mutation analysis in patients with the typical form of Anderson-Fabry disease.

[^]
409.

Ko YH et al. (1996) Atypical Fabry's disease. An oligosymptomatic variant.

[^]
410.

Ishii S et al. (1996) Aggregation of the inactive form of human alpha-galactosidase in the endoplasmic reticulum.

[^]
411.

Sawada K et al. (1996) Point mutation in the alpha-galactosidase A gene of atypical Fabry disease with only nephropathy.

[^]
412.

Blanch LC et al. (1996) A sensitive mutation screening strategy for Fabry disease: detection of nine mutations in the alpha-galactosidase A gene.

[^]
413.

Germain D et al. (1996) Fluorescence-assisted mismatch analysis (FAMA) for exhaustive screening of the alpha-galactosidase A gene and detection of carriers in Fabry disease.

[^]
414.

Brown LK et al. (1997) Pulmonary involvement in Fabry disease.

[^]
415.

Ohshima T et al. (1997) alpha-Galactosidase A deficient mice: a model of Fabry disease.

[^]
416.

Fan JQ et al. (1999) Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor.

[^]